These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
362 related items for PubMed ID: 16540766
1. Weight loss as a treatment for nonalcoholic fatty liver disease. Clark JM. J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S39-43. PubMed ID: 16540766 [Abstract] [Full Text] [Related]
2. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Tilg H, Moschen A. Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253 [Abstract] [Full Text] [Related]
9. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D. Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341 [Abstract] [Full Text] [Related]
15. Orlistat and sibutramine beyond weight loss. Mannucci E, Dicembrini I, Rotella F, Rotella CM. Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208 [Abstract] [Full Text] [Related]
16. The new role of pharmacotherapy for weight reduction in obesity. Fernstrom MH, Fernstrom JD. Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983 [Abstract] [Full Text] [Related]
17. Long-term pharmacotherapy for obesity. Klein S. Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412 [Abstract] [Full Text] [Related]
19. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Bellentani S, Dalle Grave R, Suppini A, Marchesini G, Fatty Liver Italian Network. Hepatology; 2008 Feb; 47(2):746-54. PubMed ID: 18098321 [Abstract] [Full Text] [Related]